

( (S (NP-SBJ Amgen Inc.)
     (VP said
         (SBAR 0
               (S (NP-SBJ its second-quarter earnings)
                  (VP increased
                      (ADVP more than tenfold)
                      (PP-DIR to
			      (NP (NP (QP $ 3.9 million) *U*)
				  , 
				  or
				  (NP (NP 22 cents)
				      (NP-ADV a share))))
                      ,
                      (PP-PRP due 
			      (PP to
				  (NP (NP increased sales)
				      (PP of
					  (NP (NP (NP the company 's)
						  new antianemia drug)
					      (PP for
						  (NP kidney patients)))))))))))
     .))
( (S (NP-SBJ The
             (ADJP Thousand Oaks
		   ,
		   Calif.-based)
             biotechnology company)
     (VP reported
         (NP (NP a (ADJP 97 %) increase)
             (PP-LOC in
		     (NP revenue))
             (PP to
                 (NP (QP $ 42.5 million) *U*)))
	 (PP for
	     (NP (NP the quarter)
		 (VP ended
		     (NP-TMP Sept. 30)))))
     .))
( (S (PP-TMP In
	     (NP the year-ago period))
     ,
     (NP-SBJ Amgen)
     (VP reported
         (NP (NP net income)
             (PP of
                 (NP (NP $ 320,000 *U*)
                     , or
                     (NP (NP two cents)
                         (NP-ADV a share))))
             ,
             (PP on
                 (NP (NP revenue)
                     (PP of
                         (NP (QP $ 21.5 million) *U*))))))
     .))
( (S (PP For
         (NP the six months))
     ,
     (NP-SBJ the company)
     (VP reported
         (NP (NP a
		 (ADVP more than sixfold)
		 increase)
             (PP-LOC in
		     (NP earnings))
             (PP to
                 (NP (NP (QP $ 4.7 million) *U*)
                     ,
		     or
                     (NP (NP 26 cents)
                         (NP-ADV a share))))
             ,
             (PP from
                 (NP (NP $ 625,000 *U*)
		     , 
		     or
		     (NP (NP four cents)
			 (NP-ADV a share)))
		 (ADVP-TMP (NP a year)
			   ago))))
     .))
( (S (NP-SBJ Revenue)
     (VP rose
         (NP-EXT 77 %)
         (PP-DIR to
		 (NP (QP $ 72.6 million) *U*))
         ,
         (PP-DIR from
		 (NP (NP last year 's)
		     (QP $ 41 million) 
		     *U*)))
     .))
